Last reviewed · How we verify
LhRH-antagonist — Competitive Intelligence Brief
marketed
GnRH/LhRH antagonist
GnRH receptor (LhRH receptor)
Oncology
Small molecule
Live · refreshed every 30 min
Target snapshot
LhRH-antagonist (LhRH-antagonist) — Turku University Hospital. LhRH antagonists block luteinizing hormone-releasing hormone receptors to suppress gonadotropin secretion and reduce sex hormone production.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LhRH-antagonist TARGET | LhRH-antagonist | Turku University Hospital | marketed | GnRH/LhRH antagonist | GnRH receptor (LhRH receptor) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (GnRH/LhRH antagonist class)
- Turku University Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LhRH-antagonist CI watch — RSS
- LhRH-antagonist CI watch — Atom
- LhRH-antagonist CI watch — JSON
- LhRH-antagonist alone — RSS
- Whole GnRH/LhRH antagonist class — RSS
Cite this brief
Drug Landscape (2026). LhRH-antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/lhrh-antagonist. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab